Suchergebnisse - "Fan, Ying"

PubPharm (1.459)

101

Protective effect and mechanism of Polygonatum kingianum against hypoxia-induced injury

enthalten in: Heliyon | 2023

von Li, X. | Mei, M. | Pu, X. | +9

102

Clinical characteristics and risk factors of myopic retinoschisis in an elderly high myopia population

enthalten in: Acta ophthalmologica | 2023

von Li, M. | Yu, J. | Chen, Q. | +6

103

Supramolecular Assembly of Tetramethylcucurbit[6]uril and 2-Picolylamine

enthalten in: ACS omega | 2023

von Fan, Y. | Cen, R. | Shan, P. | +4

104

Pyrotinib plus capecitabine could significantly improve overall survival in HER2-positive metastatic breast cancer

enthalten in: Signal transduction and targeted therapy | 2023

von Guan, X. | Ma, F. | Li, Q. | +7

105

Differences in texture and digestive properties of different parts in boiled abalone muscles

enthalten in: Food chemistry | 2023

von Yu, M. | Fan, Y. | Li, D. | +4

106

Characterization of CpCaM, a protein potentially involved in the growth of Cryptosporidium parvum

enthalten in: Parasitology research | 2023

von Lai, P. | Yang, X. | Li, Y. | +6

107

Correction to : Radiomics for prediction of response to EGFR-TKI based on metastasis/brain parenchyma (M/BP)-interface

enthalten in: La Radiologia medica | 2023

von Fan, Y. | Zhao, Z. | Wang, X. | +4

ErratumFor: Radiol Med. 2022 Dec;127(12):1342-1354. - PMID 36284030

108

Correction to: Radiomics for prediction of response to EGFR-TKI based on metastasis/brain parenchyma (M/BP)-interface

enthalten in: La Radiologia medica | 2023

von Fan, Y. | Zhao, Z. | Wang, X. | +4

109

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer : a pooled analysis of two phase I studies

enthalten in: Biomarker research | 2023

von Guan, X. | Ma, F. | Li, Q. | +9

110

Survival benefit and biomarker analysis of pyrotinib or pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer: a pooled analysis of two phase I studies

enthalten in: Biomarker Research | 2023

von Guan, X. | Ma, F. | Li, Q. | +9